Zouboulis CC, Okun MM, Gniadecki R, Foley PA, Lynde C, Weisman J, Karunaratne P, Williams DA. Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). J of Skin [Internet]. 2017Oct.27 [cited 2024Apr.19];1(3.1):s128. Available from: https://jofskin.org/index.php/skin/article/view/81